Ionis Pharma's genetic disease drug succeeds in late-stage study
Monday, 22 January 2024
Ionis Pharmaceuticals' experimental drug, donidalorsen, administered through subcutaneous injection, showed a significant reduction in the rate of painful attacks for patients with hereditary angioedema. The patients received an 80 milligram dose of the drug every four or eight weeks.
|
||||
You Might Like |
||||
